Back to Search Start Over

Identification of a novel proinsulin-associated SNP and demonstration that proinsulin is unlikely to be a causal factor in subclinical vascular remodelling using Mendelian randomisation

Authors :
Strawbridge, Rona J
Silveira, Angela
Hoed, Marcel Den
Gustafsson, Stefan
Luan, Jian'an
Rybin, Denis
Dupuis, Josée
Li-Gao, Ruifang
Kavousi, Maryam
Dehghan, Abbas
Haljas, Kadri
Lahti, Jari
Gådin, Jesper R
Bäcklund, Alexandra
De Faire, Ulf
Gertow, Karl
Giral, Phillipe
Goel, Anuj
Humphries, Steve E
Kurl, Sudhir
Langenberg, Claudia
Lannfelt, Lars L
Lind, Lars
Lindgren, Cecilia CM
Mannarino, Elmo
Mook-Kanamori, Dennis O
Morris, Andrew P
De Mutsert, Renée
Rauramaa, Rainer
Saliba-Gustafsson, Peter
Sennblad, Bengt
Smit, Andries J
Syvänen, Ann-Christine
Tremoli, Elena
Veglia, Fabrizio
Zethelius, Björn
Björck, Hanna M
Eriksson, Johan G
Hofman, Albert
Franco, Oscar H
Watkins, Hugh
Jukema, J Wouter
Florez, Jose C
Wareham, Nicholas J
Meigs, James B
Ingelsson, Erik
Baldassarre, Damiano
Hamsten, Anders
IMPROVE Study Group
Publisher :
Elsevier BV

Abstract

BACKGROUND AND AIMS: Increased proinsulin relative to insulin levels have been associated with subclinical atherosclerosis (measured by carotid intima-media thickness (cIMT)) and are predictive of future cardiovascular disease (CVD), independently of established risk factors. The mechanisms linking proinsulin to atherosclerosis and CVD are unclear. A genome-wide meta-analysis has identified nine loci associated with circulating proinsulin levels. Using proinsulin-associated SNPs, we set out to use a Mendelian randomisation approach to test the hypothesis that proinsulin plays a causal role in subclinical vascular remodelling. METHODS: We studied the high CVD-risk IMPROVE cohort (n = 3345), which has detailed biochemical phenotyping and repeated, state-of-the-art, high-resolution carotid ultrasound examinations. Genotyping was performed using Illumina Cardio-Metabo and Immuno arrays, which include reported proinsulin-associated loci. Participants with type 2 diabetes (n = 904) were omitted from the analysis. Linear regression was used to identify proinsulin-associated genetic variants. RESULTS: We identified a proinsulin locus on chromosome 15 (rs8029765) and replicated it in data from 20,003 additional individuals. An 11-SNP score, including the previously identified and the chromosome 15 proinsulin-associated loci, was significantly and negatively associated with baseline IMTmean and IMTmax (the primary cIMT phenotypes) but not with progression measures. However, MR-Eggers refuted any significant effect of the proinsulin-associated 11-SNP score, and a non-pleiotropic SNP score of three variants (including rs8029765) demonstrated no effect on baseline or progression cIMT measures. CONCLUSIONS: We identified a novel proinsulin-associated locus and demonstrated that whilst proinsulin levels are associated with cIMT measures, proinsulin per se is unlikely to have a causative effect on cIMT.

Details

Database :
OpenAIRE
Accession number :
edsair.doi...........789f77671339ff14d31d95b2bdc58351